RxDoctor Payments Data

Kelly Gamache

Nurse Practitioner · Flint, MINPI 1881086346

Payments from drug & device makers

$4,278in general payments, 2019–2025

Across 223 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$864
  • Otsuka America Pharmaceutical, Inc.$537
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$535
  • Axsome Therapeutics, Inc.$384
  • Takeda Pharmaceuticals U.S.A., Inc.$379
  • AbbVie$298
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,97493%
  • Education$3047%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,278 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$3,993
Medicare patients
15
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuvelityDextromethorphan Hbr/Bupropion13$14,409
Quetiapine Fumarate ErQuetiapine Fumarate40$3,977
Lurasidone Hcl23$3,420
Duloxetine Hcl74$2,881
Bupropion XlBupropion Hcl80$2,563
Buspirone Hcl62$2,424
Quetiapine Fumarate45$2,298
Venlafaxine Hcl ErVenlafaxine Hcl23$1,431
Trazodone Hcl30$1,123
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$1,041
Lamotrigine48$1,003
Methylphenidate Hcl19$906
Escitalopram Oxalate53$836
Aripiprazole35$732
Mirtazapine20$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Auvelity$384$14,40913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →